

**OptiBiotix Health plc**  
("OptiBiotix" or the "Company" or the "Group")

**New Investor Website**

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, announces the launch of a new interactive investor website. The new investor website brings all OptiBiotix content including corporate, commercial and research into a single platform to better inform and engage with prospective and existing investors and other stakeholders. The website includes:

- Announcements (RNS and Reach)
- Annual and Interim reports
- Investor presentations, podcasts and video updates
- Research publications, product and technology overviews
- Interviews with the CEO
- Interviews and videos with research/ industry partners on its technology and products

The website provides users with the ability to ask the management team questions to provide context on announcements including progress or concerns via an interactive portal which will be monitored and responded to in a timely manner. The overall aim is to give existing and prospective shareholders the opportunity to engage directly with the management team and have access to reliable information on which they can make a judgement. We would encourage all existing shareholders and prospective investors to sign up to the website (it should take less than one minute) and use it as your primary interface and information source for the business.

**How to sign up for the OptiBiotix investor website:**

1. Visit [www.optibiotix.com](http://www.optibiotix.com)
2. Follow the prompts on the top right-hand side of the website marked SIGN UP
3. Complete your account profile (name/email)

**Stephen O'Hara, Chief Executive Officer, commented:**

*"The Board is keen to improve communications with our shareholders and give them access to reliable information on which to make their investment decisions. This new 'InvestorHub' enables us to discuss commercial progress with partners, share development progress and launch plans for our second-generation products like SweetBiotix, in more depth and context than is possible through RNS announcements alone, while remaining fully compliant with market disclosure obligations.*

*We encourage all stakeholders to explore the site, engage with our content, and share their questions and feedback. Your input is invaluable as we continue refining our communication channels and building a profitable and valuable business."*

**Ends**

Engage with the OptiBiotix management team directly by asking questions, watching video summaries and seeing what other shareholders have to say.

Navigate to our Interactive Investor website here: <https://optibiotix.com/link/P2zk3P>

**Subscribe to the new website to get regular updates here:** <https://optibiotix.com/auth/signup>

**For further enquiries,** please visit [www.optibiotix.com](http://www.optibiotix.com) or contact:

<b>OptiBiotix Health PLC</b> Neil Davidson, Chairman Stephen O'Hara, Chief Executive	<a href="https://optibiotix.com/announcements">https://optibiotix.com/announcements</a>
We encourage all investors to share questions on this announcement via our investor website.	

**About OptiBiotix - [www.optibiotix.com](http://www.optibiotix.com)**

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF) OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and

manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio of technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAKZGMMRLRGVZM